- Market Capitalization, $K 3,447,941
- Shares Outstanding, K 30,890
- Annual Sales, $ 12,730 K
- Annual Income, $ -295,160 K
- 60-Month Beta 2.13
- Price/Sales 16.50
- Price/Cash Flow N/A
- Price/Book 4.97
|Period||Period Low||Period High||Performance|
| || |
+11.01 (+10.94%)since 12/27/19
| || |
-23.89 (-17.63%)since 10/25/19
| || |
-26.94 (-19.44%)since 01/25/19
GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $118.97, moving -0.13% from the previous trading session.
New Records Ahead of New Trade Deal and New Earnings Season
2020 is already a big year, we've got a presidential election, impeachment and Iranian incident. How's this going to effect our trading? It won't.
Here we discuss three best stocks in the emerging cannabis space.
The Zacks Analyst Blog Highlights: Innovative Industrial Properties, Aphria, Square and GW Pharmaceuticals
Marijuana legalization has started to ramp-up in several U.S. states. What's more, legalization of marijuana in the state of Illinois in January could bring positive tidings for the marijuana industry....
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today...
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences announced...
Passing of a legalization bill by a U.S. congressional committee boosted the battered marijuana ETF space lately.
|Gw Pharma ADR|
|Advisorshares Pure Cannabis ETF|
|Nasdaq Biotechnology Ishares ETF|
|Bldrs Europe Select ADR Index Fund Invesco|
|Bldrs Developed Markets 100 ADR Index Fund Inves|
|Nasdaq Composite ETF|